CervoMed Inc.

CRVOSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1053691

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	$9.7M	$7.1M	$0.00	—	—
Cost of Revenue	—	—	—	—	—
Gross Profit	—	—	—	—	—
Research and Development Expense	$18.8M	$8.4M	$1.3M	$8.5M	$9.4M
Operating Expenses	$28.0M	$15.0M	$3.5M	—	—
Operating Income (Loss)	-$18.2M	-$7.8M	-$3.5M	-$24.7M	-$16.0M
Interest Expense	—	—	$587.00	—	—
Nonoperating Income (Expense)	$1.9M	$5.6M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$43.1M	$10.0M	$4.2M	$37.8M	$27.7M
Assets, Current	$43.1M	$10.0M	$4.2M	$37.8M	$18.8M
Cash and Cash Equivalents, at Carrying Value	$9.0M	$7.8M	$4.1M	$37.3M	$18.5M
Liabilities	$3.9M	$2.6M	$13.2M	$2.9M	$2.9M
Liabilities, Current	$3.9M	—	—	—	$2.4M
Accounts Payable, Current	$1.5M	$662.5K	$97.3K	$947.5K	$545.8K
Stockholders' Equity Attributable to Parent	$7.4M	-$33.3M	-$33.3M	$34.9M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$16.5M	-$7.4M	-$2.6M	-$14.5M	-$13.6M
Net Cash Provided by (Used in) Investing Activities	-$28.7M	$0.00	—	$4.0K	$0.00
Net Cash Provided by (Used in) Financing Activities	$46.4M	$11.1M	$0.00	$33.3M	$17.9M
Payments to Acquire Property, Plant, and Equipment	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)